Last week, a globally active, privately held, mid-sized contract research organization (CRO) claims its research site is the very first one to dose a subject for the Janssen (J&J) ENSEMBLE study, the large, Phase 3 clinical trial investigating the vaccine candidate now known as JNJ-78436735. The company declared it was the clear lead enroller in this early part of the study, randomizing dozens of volunteers in the first week of the study. This dosing of the first study subject represents an important trial milestone. Moreover, the CTI Clinical Research Center (a trial site owned and operated by the CRO) received serious visitors last week as the top brass from the U.S. Government’s public-private partnership called Operation Warp Speed showed up there, including Dr. Moncef Slaoui, Chief Advisor and General Gustave F. Perna, Chief Operating Officer.
A Leading Trial Site
CTI’s recent press release was of course promotional in that the CRO is touting a considerable accomplishment as a marketing and industry awareness action. CTI’s CRC, a state-of-the-art facility based in Norwood, Ohio, just off the campus of Xavier University, runs Phase I-IV studies for sponsors. CTI emph...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).